Seizure-related deaths in children: The expanding spectrum

Jenna Harowitz1, Laura Crandall2,3, Declan McGuone4

  • 1University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.

Epilepsia
|February 15, 2021
PubMed

Insights

Seizures, including febrile and nonfebrile types, are an underrecognized cause of pediatric death, even in children without epilepsy. Understanding seizure-related mortality is crucial for developing preventative interventions.

Area of Science:

  • Pediatric Neurology
  • Forensic Pathology
  • Genetics

Background:

  • Seizures are common in children but frequently overlooked as a cause of death.
  • Sudden unexpected deaths in infancy, childhood, and epilepsy share common features, suggesting a link to seizure activity.
  • Increased miscarriage rates in families with epilepsy hint at seizure-related fetal loss.

Purpose of the Study:

  • To highlight the underappreciated spectrum of seizure-related mortality in children.
  • To emphasize the need for accurate estimation and mechanistic understanding of these deaths.
  • To underscore the importance of education and intervention for prevention.

Main Methods:

  • Review of clinical, neuropathological, and genetic data from sudden unexpected death syndromes.
  • Analysis of epidemiological studies on epilepsy and miscarriage rates.
  • Synthesis of existing literature on pediatric seizures and mortality.

Main Results:

  • Seizures can be fatal in children, with or without a prior epilepsy diagnosis.
  • Shared features exist between sudden unexpected infant death, sudden unexplained death in childhood, and sudden unexpected death in epilepsy.
  • Epileptic factors may contribute to fetal losses.

Conclusions:

  • The spectrum of seizure-related deaths in pediatrics is broad and underestimated.
  • Accurate assessment and understanding of seizure-related mortality mechanisms are critical.
  • Effective education and interventions are needed to prevent these tragic outcomes.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
830
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
912
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
605
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
423
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
860
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
936